CEO: Ascent's drug candidate seen as rival to Genzyme's Mozobil

09/17/2009 | Xconomy

Ascent Therapeutics says trials using animal models show its drug candidate for certain blood cancers to be as effective as Genzyme's Mozobil in stimulating stem cell movement out of the bone marrow. The drug is a potential treatment for patients with blood cancers, including non-Hodgkin's lymphoma and multiple myeloma, who require transplants of blood-forming stem cells. The drug also could be developed for use in freeing cancer cells from the bone marrow into the bloodstream to make it easier for chemotherapy drugs to eliminate them, Ascent CEO Rick Jones said.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ